A growing set of women’s health companies is developing noninvasive multiomics tests aimed at earlier endometriosis diagnosis, leveraging menstrual blood as the primary biosample. The current diagnostic standard relies on surgery to examine lesions, contributing to long delays and uncertainty in lesion testing. Companies described in the report include San Francisco-based Endometrics, which is pursuing RNA-based approaches, and Austrian firm Diamens, developing an RNA-seq endometriosis test intended for launch in Europe next year. Diamens recently closed a “six-figure” financing round to support commercialization plans. The report highlights how menstrual fluid sampling can be more accessible than invasive tissue collection, and frames the shift toward multiomic readouts—omics data types integrated for diagnosis—as a way to move diagnosis and treatment decisions earlier in the disease course.